Schrum Private Wealth Management LLC Sells 16,948 Shares of Pfizer Inc. (NYSE:PFE)

Schrum Private Wealth Management LLC cut its stake in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 54.1% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 14,354 shares of the biopharmaceutical company's stock after selling 16,948 shares during the quarter. Schrum Private Wealth Management LLC's holdings in Pfizer were worth $381,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in PFE. Retirement Wealth Solutions LLC bought a new stake in Pfizer during the 4th quarter worth about $26,000. Gladius Capital Management LP grew its holdings in shares of Pfizer by 102.8% in the 3rd quarter. Gladius Capital Management LP now owns 1,043 shares of the biopharmaceutical company's stock valued at $30,000 after buying an additional 38,015 shares during the period. Kohmann Bosshard Financial Services LLC bought a new stake in shares of Pfizer in the fourth quarter worth about $28,000. Noble Wealth Management PBC acquired a new stake in Pfizer during the 4th quarter worth approximately $31,000. Finally, Teachers Insurance & Annuity Association of America acquired a new stake in shares of Pfizer during the third quarter worth $35,000. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Pfizer Trading Up 0.7 %

PFE opened at $25.93 on Thursday. The company's 50 day moving average price is $26.31 and its two-hundred day moving average price is $27.27. The firm has a market capitalization of $146.93 billion, a price-to-earnings ratio of 18.39, a PEG ratio of 0.64 and a beta of 0.64. Pfizer Inc. has a fifty-two week low of $24.48 and a fifty-two week high of $31.54. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73.

Pfizer (NYSE:PFE - Get Free Report) last issued its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.48 by $0.15. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The company had revenue of $17.76 billion during the quarter, compared to the consensus estimate of $17.26 billion. During the same period last year, the company earned $0.10 earnings per share. The firm's revenue was up 24.7% compared to the same quarter last year. As a group, research analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, March 7th. Shareholders of record on Friday, January 24th will be issued a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.63%. This is a boost from Pfizer's previous quarterly dividend of $0.42. The ex-dividend date of this dividend is Friday, January 24th. Pfizer's dividend payout ratio is presently 121.99%.

Wall Street Analyst Weigh In

PFE has been the subject of a number of recent research reports. Wolfe Research started coverage on Pfizer in a research report on Friday, November 15th. They set an "underperform" rating and a $25.00 price target for the company. StockNews.com cut Pfizer from a "strong-buy" rating to a "buy" rating in a research note on Wednesday, November 20th. Truist Financial lowered their target price on Pfizer from $36.00 to $32.00 and set a "buy" rating on the stock in a research note on Wednesday, December 18th. UBS Group cut their price objective on shares of Pfizer from $31.00 to $29.00 and set a "neutral" rating for the company in a report on Wednesday, January 8th. Finally, Citigroup decreased their price target on Pfizer from $30.00 to $29.00 and set a "neutral" rating on the stock in a research report on Tuesday, January 28th. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating, six have issued a buy rating and two have assigned a strong buy rating to the company's stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average target price of $31.92.

Insiders Place Their Bets

In other news, Director Ronald E. Blaylock bought 19,457 shares of the stock in a transaction dated Thursday, February 13th. The shares were bought at an average cost of $25.65 per share, with a total value of $499,072.05. Following the completion of the transaction, the director now directly owns 27,707 shares of the company's stock, valued at $710,684.55. This trade represents a 235.84 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Corporate insiders own 0.06% of the company's stock.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.